Results 51 to 60 of about 36,524 (294)

Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]

, 2017
AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA, BASILI, Stefania, LA TORRE, Giuseppe, LENZI, TOMMASO, PACELLA, Elena, PACELLA, FERNANDA, Pascarella, Antonella   +6 more
core   +1 more source

In Vitro Cell Models for Ophthalmic Drug Development Applications [PDF]

, 2016
© Sara Shafaie et al. 2016; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and ...
Ahmed I, Aliyar HA, Araki K, Araki K, Araki-Sasaki K, Barar J, Basu SK, Cakmak HB, Calabrese EJ, Campbell M, Chang C-W, Curren RD, Davis AA, Defoe DM, Dewhurst DG, Draize JH, Eskes C, Ghassemi A, Gillies MC, Gukasyan HJ, Haeseleer F, Hoffmann S, Hu J, Huang W, Huhtala A, Kahn C, Kaida M, Kawazu K, Kennedy BG, Kulkarni AA, Lu SC, Minami Y, Nabi IR, Offord EA, Okamoto S, Rathore K, Saha P, Schneider A, Swindle KE, Tchao R, Thuret G, Toropainen E, Toropainen E, Tripathi B, Trone M, Xiang G, Zech J-C   +46 more
core   +3 more sources

Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations : design, characterisation, toxicity and transcorneal permeation studies [PDF]

, 2017
This study was aimed at preparing, characterising and evaluating in situ gel formulations based on a blend of two hydrophilic polymers i.e. poloxamer 407 (P407) and poloxamer 188 (P188) for a sustained ocular delivery of ketorolac tromethamine (KT). Drug-
Abdelkader, Abdelkader, Abdelkader, Abdelkader, Abdelkader, Abdelkader, Abdelkader, Abdelkader, Abou El-elaa, Ajit, Al Khateb, Alany, Almeida, Amal K. Hussein, Angius, Anil Vangala, Asasutjarit, Attama, Auerbach, Baeyens, Baklayan, Baloglu, Chena, Dohle, Dumortier, El-Kamel, Faber, Fathalla, Fernández-Ferreiro, Garg, Gupta, Hao, Heilmann, Kadam, Khaled A. Khaled, Kim, Kim, Law, Li, Ling, Luepke, Mansour, Mayol, Michael Longman, Mosmann, Mythri, Nanjawade, Nanjwadea, Newa, Omar H. El-Garhy, Qi, Raid G. Alany, Riccia, Rooks, Rossi, Rupenthal, Rupenthala, Schoenwald, Sinha, Sintzel, Sunil, Thakor, Thrimawithana, Thrimawithanaa, Vadnere, Verstraelen, Walters, Wei, Weterings, Worakul, Xu, Yang, Zeinab M.A. Fathalla   +72 more
core   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources

Extended Latanoprost Release from Commercial Contact Lenses: In Vitro Studies Using Corneal Models [PDF]

, 2014
Mohammadi, S., Jones, L., & Gorbet, M. (2014). Extended Latanoprost Release from Commercial Contact Lenses: In Vitro Studies Using Corneal Models. PLoS ONE, 9(9), e106653.
Gorbet, Maud, Jones, Lyndon W., Mohammadi, Saman   +2 more
core   +2 more sources

Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release ocular delivery

, 2017
The goal of the present study is to develop polymeric matrix films loaded with a combination of free diclofenac sodium (DFSfree) and DFS:Ion exchange resin complexes (DFS:IR) for immediate and sustained release profiles, respectively.
Adelli, Goutham R., Balguri, Sai Prachetan, Bhagav, Prakash, Majumdar, Soumyajit, Raman, Vijayasankar   +4 more
core   +2 more sources

Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy

Journal of Nanobiotechnology, 2023
Ophthalmic inflammatory diseases, including conjunctivitis, keratitis, uveitis, scleritis, and related conditions, pose considerable challenges to effective management and treatment.
Jing Wei, Jinyu Mu, Yong Tang, Dalian Qin, Junguo Duan, Anguo Wu   +5 more
doaj   +1 more source

Ophthalmic Drug Delivery through Contact Lenses

Investigative Opthalmology & Visual Science, 2004
Currently available ophthalmic drug delivery systems are inefficient and may lead to side effects. To increase efficiency and reduce side effects, the authors propose disposable particle-laden soft contact lenses for ophthalmic drug delivery.The essential idea is to encapsulate the ophthalmic drug formulations in nanoparticles and to disperse these ...
Derya, Gulsen, Anuj, Chauhan
openaire   +2 more sources

Precise Control of Drug Release in Machine Learning‐Designed Antibody‐Eluting Implants for Postoperative Scarring Inhibition in Glaucoma

Advanced Healthcare Materials, EarlyView.
We developed a micro‐sized, biocompatible implant for postoperative sustained delivery of anti‐fibrotic antibodies in glaucoma surgery. Machine learning‐guided optimization of polymer composition, implant geometry, and porosity enabled precise control of drug release.
Mengqi Qin, Wenbing Jiang, Kai Xin Thong, Zeynep Ulker, Brihitejas Patel, Cynthia Yu‐Wai‐Man   +5 more
wiley   +1 more source

Nanoparticles laden in situ gelling system for ocular drug targeting

Journal of Advanced Pharmaceutical Technology & Research, 2013
Designing an ophthalmic drug delivery system is one of the most difficult challenges for the researchers. The anatomy and physiology of eye create barriers like blinking which leads to the poor retention time and penetration of drug moiety.
Divya Kumar, Nidhi Jain, Neha Gulati, Upendra Nagaich   +3 more
doaj   +1 more source